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Abstract
Background: Recently, it has been observed that mesenchymal stem cells (MSCs) can modulate their
immunoregulatory properties depending on the specific in-vitro activation of different Toll-like receptors (TLR),
such as TLR3 and TLR4. In the present study, we evaluated the effect of polyinosinic:polycytidylic acid (poly(I:C))
and lipopolysaccharide (LPS) pretreatment on the immunological capacity of MSCs in vitro and in vivo.
Methods: C57BL/6 bone marrow-derived MSCs were pretreated with poly(I:C) and LPS for 1 hour and their
immunomodulatory capacity was evaluated. T-cell proliferation and their effect on Th1, Th17, and Treg
differentiation/activation were measured. Next, we evaluated the therapeutic effect of MSCs in an experimental
autoimmune encephalomyelitis (EAE) model, which was induced for 27 days with MOG35–55 peptide following the
standard protocol. Mice were subjected to a single intraperitoneal injection (2 × 106 MSCs/100 μl) on day 4. Clinical
score and body weight were monitored daily by blinded analysis. At day 27, mice were euthanized and draining
lymph nodes were extracted for Th1, Th17, and Treg detection by flow cytometry.
Results: Pretreatment of MSCs with poly(I:C) significantly reduced the proliferation of CD3+ T cells as well as nitric
oxide secretion, an important immunosuppressive factor. Furthermore, MSCs treated with poly(I:C) reduced the
differentiation/activation of proinflammatory lymphocytes, Th1 and Th17. In contrast, MSCs pretreated with LPS
increased CD3+ T-cell proliferation, and induced Th1 and Th17 cells, as well as the levels of proinflammatory
cytokine IL-6. Finally, we observed that intraperitoneal administration of MSCs pretreated with poly(I:C) significantly
reduced the severity of EAE as well as the percentages of Th1 and Th17 proinflammatory subsets, while the
pretreatment of MSCs with LPS completely reversed the therapeutic immunosuppressive effect of MSCs.
Conclusions: Taken together, these data show that pretreatment of MSCs with poly(I:C) improved their
immunosuppressive abilities. This may provide an opportunity to better define strategies for cell-based therapies
to autoimmune diseases.
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Background
Mesenchymal stem cells (MSCs) are nonhematopoietic,
multipotent progenitor cells isolated from a variety of
adult tissues, including bone marrow and adipose tissue.
They are capable of self-renewal and are able to differenti-
ate into at least some mesenchymal cell types, such as
bone, cartilage, and fat, thus playing a potential role in
tissue repair [1, 2]. In addition to their potential for differ-
entiation, MSCs also exhibit immunosuppressive activity,
as shown by their ability to inhibit the proliferation and
function of immunocompetent cells, such as T and B
lymphocytes, natural killer cells, and dendritic cells [3–5].
These immunomodulatory properties of MSCs have gen-
erated great interest in their potential as a promising
therapeutic modality for proinflammatory and auto-
immune diseases [6, 7]. Diverse studies using experimental
animal models have shown that MSCs can reduce the
progression and/or severity of various immune-mediated
diseases, such as collagen-induced arthritis (CIA) [8],
experimental colitis [9], and experimental autoimmune
encephalomyelitis (EAE) [10, 11]. In addition, we recently
demonstrated that the intravenous administration of
MSCs in EAE at different stages of the disease induced
differential therapeutic effects depending on the proin-
flammatory environment at each stage of the disease [12].
It has also been demonstrated that the immunosup-
pressive activity of MSCs does not seem to be spontan-
eous but instead requires MSCs to be “licensed” in an
appropriate proinflammatory environment to exert their
effects [13, 14]. In this line, Krampera et al. and Ren et
al. showed that MSCs mediating immunosuppression re-
quired preliminary activation by immune cells through
the secretion of the proinflammatory cytokine IFN-γ, ei-
ther alone or together with TNF-α, IL-1α, or IL-1β [3,
15]. These cytokine combinations induced the MSCs to
express high levels of soluble factors involved in MSC-
mediated immunosuppression, such as indoleamine 2,3-
dioxygenase (IDO), transforming growth factor beta
(TGF-β), prostaglandins, and nitric oxide (NO), as well
as other factors [3, 15–17].
In addition to activation of MSCs by proinflammatory
cytokines, Toll-like receptors (TLRs) can influence their
immunomodulatory capacity. For example, Liota et al.
[18] showed that human bone marrow-derived MSCs
(BM-MSCs) express high levels of TLR3 and TLR4, and
that ligation of these receptors by their agonists, polyi-
nosinic:polycytidylic acid (poly(I:C)) and lipopolysac-
charide (LPS), respectively, can reduce the inhibitory
activity of MSCs on CD4+ T-cell proliferation. In
contrast, Opitz et al. showed that pretreatment of
human BM-MSCs for 24 hours with poly(I:C) or LPS
significantly enhanced the immunosuppressive activity of
BM-MSCs on the allo-mixed lymphocyte reaction
(MLR) [19]. On the contrary, recent results demonstrate
that human MSCs polarize into two active phenotypes
following specific TLR3 or TLR4 activation. Priming by
TLR3 agonists specifically leads to the expression of
immune dampening mediators and the maintained sup-
pression of T-cell activation. In contrast, priming by
TLR4 agonists results in the expression of proinflamma-
tory mediators and a reversal of the MSC-established
suppressive mechanisms of T-cell activation [20]. Besides
these in-vitro studies, our group recently demonstrated
that TLR3 preconditioning increases the therapeutic effi-
cacy of human umbilical cord MSCs in a mouse model
of colitis [21]. These results demonstrate the complexity
of the immunomodulatory capacity of MSCs and suggest
that TLR activation may affect the functional immune
activity of MSCs.
The aim of the present study was to demonstrate, for
the first time in murine MSCs and an experimental
model of multiple sclerosis (EAE), that in-vitro pretreat-
ment of MSCs with poly(I:C) or LPS can induce two
distinct active phenotypes in MSCs, as found in humans,
and that these polarized cells possess opposite immuno-
logical effects in vitro and in vivo. Our results indicate
that pretreatment of MSCs with poly(I:C) enhances their
immunosuppressive capacity on T lymphocytes and that
the intraperitoneal injection of these MSCs significantly
reduces the severity of EAE. In contrast, LPS-pretreated
MSCs induced a significant increase in T-cell prolifera-
tion and completely reversed the immunosuppressive
therapeutic effect of MSCs in EAE.
Methods
Animals
Female C57BL/6 mice, 8–14 weeks old, were purchased
from the central animal facility of the Faculty of Medi-
cine, University of Chile. Animals were housed under
standard laboratory conditions and provided food and
water ad libitum. Experimental procedures and protocols
were performed according to the US National Institute
of Health Guide for the care and use of laboratory
animals (NIH Publication No. 85-23, revised 1996), and
were approved by the institutional animal care and use
committee of the Universidad de los Andes and the
FONDECYT bioethics advisory committee in Chile.
MSC culture in vitro
MSCs (GIBCO Mouse (C57BL/6), catalog number
S1502-100) were obtained from bone marrow isolated
from C57BL/6 mice at ≤ 8 weeks of age through mech-
anical and enzymatic digestion. Cells were cultured in
complete alpha modified Eagle’s medium (αMEM;
Gibco, Auckland, New Zealand) containing 10 % heat-
inactivated MSCs, qualified fetal bovine serum (FBS;
Gibco), 100 U/ml penicillin, and 100 μg/ml streptomycin
(Gibco), and incubated at 37 °C with 5 % CO2. At
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subconfluence, cells were replated at a density of 5000
cells/cm2 and used between passages 9 and 12.
MSC characterization
The MSC phenotype was confirmed by flow cytometry
based on the positivity for CD29, CD44, and Sca-1, in
the absence of CD45 and C11b antigen. All antibodies
were purchased from BD Biosciences (San Diego, CA,
USA). Surface staining was performed following a standard
protocol. The samples were acquired with a FACSCanto II
flow cytometer (Becton, Dickinson and Company). Data
were analyzed using FCS Express 4 Plus research edition
and Flow Jo software. Determination of the capacity
of MSCs to differentiate toward chondrogenic, adipo-
genic, and osteogenic lineages was performed as de-
scribed previously [22].
Treatment of MSCs
MSCs were grown to 70–80 % confluence and incubated
with agonists for 1 hour in complete αMEM. For TLR
pretreatment of MSCs, poly(I:C) (10 μg/ml; Sigma-
Aldrich, Israel) and LPS (500 ng/ml; Sigma-Aldrich,
Israel) were used as agonists for TLR3 and TLR4, re-
spectively. Cells were then washed thoroughly with a
complete cell culture medium before use in the different
assays described in the following.
Quantitative real-time PCR analysis
For the evaluation of MSC gene expression, after pre-
treatment with poly(I:C) and LPS for 1 hour, cells were
thoroughly washed and cultured for 12 hours in
complete αMEM. Cells were then harvested using Tryp-
sin 1× (Trypsin–EDTA 1×; Gibco) and pelleted. Total
RNA was isolated using the RNeasy Mini Kit (Qiagen)
following the manufacturer’s instructions. The RNA
concentration was measured with a NanoDrop 2000
spectrophotometer (Thermo Scientific), and cDNA was
synthesized from 2 μg of RNA using a reverse transcrip-
tion protocol (Improm II-RT, A3802; Promega). Quanti-
tative real-time PCR (RT-qPCR) was performed in a
Stratagene MX3000P thermocycler (Agilent Technolo-
gies) using GoTaq qPCR Mastermix (Promega, Madison,
WI, USA). 18S was used to normalize the results, and
basal conditions were used for calibration. MxPro v4.10d
software was used for analysis using the 2–(ΔΔCt) formula,
where ΔΔCt takes into account the efficiency of the
primers and the normalized Ct values. The primer
sequences used for amplification are presented in Table 1.
Proliferation assays
Splenocytes were obtained from the spleen of adult
C57BL/6 mice. Extracted cells were passed through a
70-μm filter (cell strainer; BD Falcon), centrifuged at
1680 rpm for 6 minutes, and treated with cold NH4Cl
for 5 minutes. Cells were then washed in PBS (phos-
phate-buffered saline) and centrifuged at 1680 rpm for
6 minutes. Next, cells were labeled with CellTrace Violet
(CTV) (Invitrogen, UK) according to the manufacturer’s
instructions. For T-cell activation, 2 × 105 cells were
stimulated with concanavalin A (conA) (0.5 μg/ml) in
the presence or absence of MSCs at a 1:10 ratio
(MSCs:splenocytes) in complete RPMI medium with
10 % FBS, 100 U/ml penicillin, and 100 μg/ml strepto-
mycin (Gibco) at 37 °C in a 5 % CO2 atmosphere. After
5 days of culture, cells were washed and evaluated by
flow cytometry for the percentage of CD3+ T cells in the
population. For the proliferation analysis, we used CTV,
which functions similarly to standard CFSE staining.
CTV was added at the beginning of the cultures. Each
peak on the histograms corresponds to the division
cycles for CD3+ lymphocytes. After obtaining the num-
ber of events, we calculated a proliferation index that
incorporated the number of cells divided by the number
of progenitors as described by Roederer [23].
In-vitro T-helper cell differentiation
Purified CD4+ T cells were isolated from C57BL/6 sple-
nocytes using the Dynabeads untouched mouse CD4
Cell kit (Invitrogen) according to the manufacturer’s in-
structions. Purified CD4+ T lymphocytes were cultured
in RPMI Medium 1640 with GlutaMAX supplemented
with 10 % FBS, 1 units/ml penicillin/0.1 mg/ml strepto-
mycin, 1 mM sodium pyruvate, 20 mM HEPES, and
50 μM of β-mercaptoethanol (Invitrogen, Grand Island,
NY, USA). T cells were stimulated in 48-well plates
coated with anti-CD3 (2 μg/ml) and anti-CD28 (1 μg/
ml) antibodies (BD Biosciences, San Diego, CA, USA)
and were subjected to specific T-cell differentiation. Th1
differentiation was induced by adding 5 ng/ml of IL-12
and 2.5 μg/ml of anti-IL-4. Th17 differentiation was in-
duced by adding TGF-β (5 ng/ml), IL-6 (50 ng/ml), and
IL-23 (5 ng/ml) and neutralizing antibodies for IFN-γ
and IL-4 (2.5 μg/ml each). Each stimulation period
lasted 5 days. T cells were plated into the wells, and
MSCs were added in a 1:10 ratio (MSCs:CD4+ T cells).
For FACS analysis, differentiated Th1 and Th17 cells
were restimulated with PMA/ionomycin for 3.5 hours in
the presence of brefeldin for the last 2.5 hours of
incubation at 37 °C before antibody staining.
Th1 and Th17 FACS analysis
Differentiated T cells were stained with an anti-CD4 PE-
conjugated antibody (BD Biosciences) for 30 minutes at
4 °C in staining buffer. Intracellular staining was per-
formed using a CytoFix/Cytoperm kit (BD Bioscience)
following the manufacturer’s instructions. Cells were
stained with anti-IFN-γ (FITC-conjugated) antibody for
the Th1 subset of the population, or an anti-IL-17A
Vega-Letter et al. Stem Cell Research & Therapy  (2016) 7:150 Page 3 of 12
(PE-conjugated) antibody for the Th17 subset of the
population. After membrane and intracellular staining,
cells were analyzed with a FACSCanto II using the
FACS Express software. For the proliferation analysis,
we used CTV, which functions similarly to standard
CFSE staining. CTV was added at the beginning of the
cultures. Each peak on the histograms corresponds to
the division cycles for CD4+IFN-γ+ and CD4+IL-17+ lym-
phocytes, corresponding to Th17 and Th1 lymphocytes,
respectively. After obtaining the number of events, we
calculated a proliferation index that incorporated the
number of cells divided by the number of progenitors.
EAE induction and treatment
Female C57BL/6 mice (10–14 weeks old) were injected
subcutaneously (s.c.) in the flank with 50 μg of MOG35–55
peptide (LifeTein LCC, USA) emulsified in a complete
Freund’s adjuvant (Difco Laboratories, Detroit, MI, USA)
supplemented with heat-inactivated Mycobacterium tuber-
culosis H37RA (Difco Laboratories). Subsequently, 2 and
48 hours later, mice received 350 ng of pertussis toxin
(Calbiochem, La Jolla, CA, USA) intraperitoneally (i.p.).
Clinical signs appeared 10 days after EAE induction as
described previously [24] . Thus, to evaluate the therapeutic
effect of untreated MSCs or MSCs pretreated with
poly(I:C) and LPS, mice were injected i.p. on day 4 with
2 × 106 MSCs in 100 μl of PBS.
Score analysis
Mice were monitored daily by a blinded observer for
behavioral EAE symptoms, scored, and weighed, as
reported previously [12], for 27 days. Classical EAE
scores were assigned as follows: 0 = no disease; 0.5 =
reduced tail tonus; 1 = limp tail; 1.5 = limp tail and ataxia;
2 = limp tail, ataxia, and hind-limb weakness; 2.5 = at least
one hind limb paralyzed/weak; 3 = both hind limbs para-
lyzed/weak; 3.5 = complete paralysis of hind limbs; 4 =
paralysis to hip; and 5 =moribund or dead.
ELISA for cytokines
Culture supernatants were assayed for IL-6 using an
ELISA kit (catalog number DY406; R&D systems) accord-
ing to the manufacturer’s protocol.
Measurement of iNOS activity
NO was detected using a modified Griess reagent
(Sigma-Aldrich). Briefly, all NO3 was converted into
NO2 by nitrate reductase, and total NO2 was detected
by the Griess reaction as described previously [25].
Ex-vivo T-cell analysis
For ex-vivo T-cell analyses, draining inguinal and axillary
lymph nodes were removed from mice 27 days after
EAE induction. T cells were obtained and cultured at a
density of 2.5 × 105/well. Inflammatory cells were restim-
ulated with PMA/ionomycin for 3.5 hours in the pres-
ence of brefeldin A for the last 2.5 hours of incubation
at 37 °C before antibody staining and analysis by flow
cytometry. Next, Th1 and Th17 cells in the samples
from the different groups were identified as already
described. Finally, after membrane and intracellular
staining, cells were analyzed with a FACSCanto II using
the FACS Express software.
Statistical analysis
A Kruskal–Wallis test, which accounts for non-normal
distributions with small sample sizes and multiple
groups, was performed for comparisons between experi-
mental groups. Post-hoc analyses were performed with
the Mann–Whitney test. For all analyses, we used
GraphPad Prism Program (GraphPad, San Diego, CA,
USA) statistical software. p < 0.05 was considered statis-
tically significant. Data are presented as the mean ±
standard deviation.
Results
Characterization and TLR expression of MSCs
Murine MSCs were cultured in complete αMEM for the
selective proliferation of MSCs. After culturing, cells
with a stable fibroblast-like phenotype were used for
experimentation (Fig. 1a). As evidenced by flow cy-
tometry, cells were uniformly and strongly positive for
MSC-related markers, such as CD44, CD29, and Sca-
1 (80–99 %), and were negative for CD45 and CD11b
(<4 %) (Fig. 1c). As shown in Fig. 1c, we confirmed
the ability of MSCs to differentiate into adipocytes,
chondrocytes, and osteoblasts using a specific differ-
entiation stimulus (right) or control medium (left) as
described in Methods. We next examined the relative
Table 1 mRNA primer information
Gene name Forward primer (5ʹ a 3′) Reverse primer (5′ a 3′) Access Number Gene Bank
TLR3 AAAACTCAGCGGCCAGGAAT AGTTACGAAGAGGGCGGAAA NM_126166.4
TLR4 TGGCTGGTTTACACGTCCAT GCAGAAACATTCGCCAAGCA NM_021297.2
18s ATCGCCAGTCGGCATCGTTTAT GCCGCTAGAGGTGAAATTCTTGGA NR_003286.2
Abbreviations: TLR3, toll like receptor 3; TLR4, toll like receptor 4; 18S, 18S ribosomal RNA
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expression of TLR3 and TLR4 genes in MSCs using
RT-qPCR and gel electrophoresis. RT-qPCR and
agarose gel electrophoresis analysis revealed that
murine MSCs expressed both TLRs and that the
expression level of TLR4 was higher than TLR3
(Fig. 1d, e). We also found that pretreatment of
MSCs with poly(I:C) and LPS for 1 hour did not
affect the immunophenotypic profile of murine
MSCs (data not shown).
TLR3 and TLR4 pretreatment differentially affect the
in-vitro immunosuppressive capacity of murine MSCs
To evaluate the effect of specific stimulation of TLR3
and TLR4, we treated the MSCs for 1 hour with
poly(I:C) or LPS in complete αMEM and then
determined their in-vitro immunomodulatory capacity.
First, we tested the immunosuppressive capacity of
MSCs to inhibit T-cell proliferation induced by conA.
Briefly, splenocytes were isolated from C57BL/6 mice,
stained with CTV (a fluorescent dye used to determine
T-lymphocyte proliferation), and then stimulated with
ConA for 3 days. Flow cytometry was used to analyze
the proliferation of CD3+ T lymphocytes that were
cultured in the presence or absence of untreated MSCs
or MSCs pretreated with poly(I:C) or LPS at different
MSC:splenocyte ratios (1:5, 1:10, and 1:20), as described
in Methods.
The addition of MSCs to the T-cell cultures significantly
decreased the proliferation of CD3+ T lymphocytes in a





Fig. 1 Characterization of murine MSCs and TLR expression. (a) Morphology and characteristics of murine BM-MSCs (20× magnification).
(b) Immunophenotypic profile from a representative murine MSC population. Cell surface markers, solid red; isotype cell controls, gray. (c) MSCs were
confirmed to have the capacity to differentiate into chondrocytes, osteoblasts, and adipocytes (right) by alizarin red, safranin O, and oil red
staining (4, 10, and 40× magnification, respectively), as described in Methods. Respective controls (culture medium only, without differentiation
conditions) (Left). (d) Relative expression of TLR3 and TLR4 in MSCs confirmed by RT-qPCR normalized with 18S = 1 × 10–5 as described
previously [37] (n = 3). (e) RT-qPCR products were analyzed by 2.5 % agarose gel electrophoresis along with a low-range DNA ladder (MW).
Negative control, without cDNA template. MW molecular weight. *p < 0.05, **p < 0.01, ***p < 0.001
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the control condition (without MSCs) (p < 0.05, Fig. 2a).
MSCs pretreated with poly(I:C) for 1 hour were consider-
ably more effective than untreated MSCs in inhibiting T-
cell proliferation at the different ratios analyzed (p < 0.001,
Fig. 2a). In contrast, MSCs pretreated with LPS for 1 hour
not only reversed the immunosuppressive effect of MSCs
but also induced a significant increase in T-cell prolifera-
tion in a dose-dependent manner compared with the
effects in the control condition (p < 0.001, Fig. 2a).
We next studied the effect of poly(I:C) and LPS pre-
treatment of murine MSCs on the expression of immune
modulators, such as the soluble immunosuppressive
factors NO and proinflammatory cytokine IL-6. Super-
natants derived from MSCs cultured in complete αMEM
for hours in the absence or presence of splenocytes were
used to evaluate the presence of NO, as described in
Methods. A modified Griess assay for nitrite quantita-
tion showed no significant differences in NO secreted by
untreated or pretreated MSCs (data not shown). How-
ever, when MSCs were cultured in the presence of
splenocytes, we observed a significant increase in NO
production induced by the MSCs pretreated with poly(I:C)
compared with untreated MSCs (p < 0.001, Fig. 2b).
Conversely, pretreatment of MSCs with LPS induced lower
NO production in comparison with untreated MSCs or
MSCs pretreated with poly(I:C) (p < 0.001, Fig. 2b).
Quantitative analysis of IL-6 expression, evaluated by
RT-qPCR, revealed that MSCs pretreated with LPS in-
duced a significant increase in the relative expression of
IL-6 compared with untreated MSCs or poly(I:C) pre-
treated MSCs (p < 0.05, Fig. 2c). No significant differences
were observed in mRNA IL-6 expression between un-
treated MSCs and MSCs pretreated with poly(I:C). We
also observed that MSCs pretreated with LPS had higher
IL-8 mRNA expression than untreated MSCs or MSCs
pretreated with poly(I:C) (data not shown). Moreover, we
observed that MSCs pretreated with poly(I:C) lose the
capacity to secrete IL-6, as measured by ELISA after
24 hours of stimulation, compared with the observed IL-6
secretion in untreated MSCs and MSCs pretreated with
LPS (p < 0.001, Fig. 2d). These results suggest that MSCs
pretreated for 1 h with poly(I:C) have a higher immuno-
suppressive effect in vitro when compared with untreated
MSCs or MSCs pretreated with LPS.
Pretreatment of murine MSCs with poly(I:C) or LPS
induces different and opposing in-vitro effects on Th1
and Th17 subsets
We next studied the immunomodulatory effect of the
addition of untreated murine MSCs or MSCs pretreated
with poly(I:C) or LPS for 1 hour on in-vitro differenti-




Fig. 2 Immunomodulatory capacity of MSCs stimulated with TLR3 and TLR4 ligands in vitro. (a) To study the immunosuppressive capacity of
untreated MSCs and MSCs pretreated for 1 hour with poly(I:C) or LPS on T-cell response, we performed an in-vitro T-cell stimulation assay at different
ratios of MSCs:splenocytes, as described in Methods. MSCs were either unstimulated or were stimulated with poly(I:C) (10 μg/ml) or LPS (500 ng/ml)
for 1 hour before being cocultured with T cells in complete RPMI medium. Previously, splenocytes were labeled with CTV and stimulated with Con A
and finally cultured with MSCs at 1:5, 1:10, or 1:20 ratios for 3 days. T-cell proliferation was evaluated by flow cytometry, gating on CD3+ cells.
(b) Secretion of nitric oxide (NO) by MSCs in coculture with splenocytes at a 1:10 ratio was measured using a modified Griess reagent. (c) IL-6 mRNA
expression evaluated by RT-qPCR. (d) IL-6 secretion, measured by ELISA. Data expressed as the mean ± SED. A Mann–Whitney test was performed,
*p < 0.05, **p < 0.01,***p < 0.001. MSCsPoly MSCs pretreated with poly(I:C) for 1 hour, MSCsLPS MSCs pretreated with LPS for 1 hour








Fig. 3 MSCs stimulated with TLR3 and TLR4 ligands differentially modulate Th1 and Th17 differentiation and proliferation. T-helper cell differentiation
(a, b, e, f) and proliferation (c, d, g, h) were assessed using naïve CD4+ T cells. Purified CD4+ cells were stimulated with a specific cocktail of cytokines,
as described in Methods, to induce Th1 (a–d) and Th17 (e–h) differentiation in the absence or presence of MSCs pretreated with or without a TLR agonist.
MSCs were either unstimulated or were stimulated with poly(I:C) (10 μg/ml) or LPS (500 ng/ml) for 1 hour before being cocultured with CD4+ T cells in
complete RPMI medium. MSCs were added at day 0 of the differentiation process in a 1:10 ratio (MSCs:T cells). Flow cytometry analysis, gating on CD4+
cells, and intracellular staining, using antibodies (mAb) for IFN-γ and IL17 to identify Th1 and Th17 lymphocytes, respectively, were performed. Representa-
tive density plots of six different experiments for Th1 and Th17 differentiation are shown. For proliferation analysis, CD4+ cells were previously labeled
with CellTrace Violet (CTV) and analyzed (presented as histograms). Further analysis of the events of each cycle, described by the proliferation index (d, h).
Th1 differentiation (b) and proliferation (d) with the MSCs pretreated with poly(I:C) and LPS. Th17 differentiation (f) and proliferation (h) with the MSCs
pretreated with poly(I:C) and LPS. Bars represent the mean ± SEM, significant differences calculated using the Mann–Whitney test. *p< 0.05, **p< 0.001.
MSCsPoly MSCs pretreated with poly(I:C) for 1 hour, MSCsLPS MSCs pretreated with LPS for 1 hour
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CD4+ T lymphocytes, purified by negative selection
from splenocytes, were stained with CTV and cul-
tured under Th1 and Th17 polarizing conditions in
the absence or presence of TLR3 or TLR4-stimulated
MSCs. MSCs were added at the beginning of the
differentiation protocol at a 1:10 ratio (MSCs:CD4+
T cells) and intracellular cytokines for Th1 and Th17
cells were evaluated at day 5 by flow cytometry, as
described in Methods.
The patterns of Th1 and Th17 differentiation and
proliferation for six different experiments are shown in
Fig. 3a, e. The data analysis summary of the proliferation
is shown in Fig. 3b, f.
As shown in Fig. 3a, b, the addition of untreated
MSCs significantly suppressed the clonal expansion of
IFN-γ-secreting (Th1) cells relative to that we re-
ported previously [22]. (p < 0.05, Fig. 3a, b). The pre-
treatment of MSCs with poly(I:C) induced a higher
capacity to inhibit Th1 than was observed in un-
treated MSCs (p < 0.05). Although not significantly
different, the addition of MSCs treated with poly(I:C)
also induced a decrease in the proliferation of Th1
cells compared with that in untreated MSCs (Fig. 3c, d).
In contrast, culturing Th1 cells with MSCs pretreated with
LPS showed that these MSCs had a reduced ability to
inhibit Th1 differentiation and proliferation in comparison
a
b c
Fig. 4 MSCs treated with poly(I:C) or LPS generate distinct immunomodulatory effects in an EAE model. Data show EAE clinical signs according
to the different treatments of MSCs (either pretreated or not with TLR3 and TLR4 ligands). EAE was induced in C57BL/6 mice (n = 10/group) by
subcutaneous immunization with 50 μg of MOG35–55 peptide, as described in Methods. MSC controls and MSCs pretreated with poly(I:C) or LPS
were injected i.p. at day 4 (2 × 106/mouse) as described in Methods. (a) Scores were measured daily at the same time for 27 days and given a
value of 0–5 according to loss of mobility in the lower and upper extremities. (b) The sum of the scores from day 10 to the end of the
experiment was pooled by treatment group. Poly(I:C)-pretreated MSCs show a significantly lower cumulative score than that of EAE control mice.
(c) Body weight loss (%), measured daily and clustered by treatment. A Wilcoxon rank test was used for comparisons with the untreated MSCs.
*EAE +MSCsPoly compared with EAE and **EAE + MSCsLPS compared with EAE +MSCs with the matched pairs test, p < 0.001. MSCsPoly MSCs
pretreated with poly(I:C) for 1 hour, MSCsLPS MSCs pretreated with LPS for 1 hour
Vega-Letter et al. Stem Cell Research & Therapy  (2016) 7:150 Page 8 of 12
with the effect of untreated MSCs (p < 0.05). Regarding
the ability of MSCs to inhibit the clonal expansion of IL-
17-secreting (Th17) lymphocytes, we observed that un-
treated MSCs significantly inhibited Th17 differentiation
(p < 0.05, Fig. 3e, f ). Furthermore, Th17 cultured with
MSCs showed a decrease in Th17 proliferation, although
these differences were not statistically significant (Fig. 3e,
f ). Similar to the pattern observed with Th1 cells, MSCs
pretreated with LPS showed a decreased effect on Th17
differentiation compared with that observed in untreated
MSCs and MSCs pretreated with poly(I:C) (p < 0.05,
Fig. 3e, f ). Finally, MSCs pretreated with LPS exhibited in-
creased Th17 proliferation compared with the effect of
MSCs pretreated with poly(I:C) (p < 0.05, Fig. 3 g, h).
These results showed that brief pretreatment of murine
MSCs with poly(I:C) or LPS induces different and oppos-
ing effects on Th1 and Th17 cell differentiation and prolif-
eration, suggesting that stimulation of murine MSCs with
TLRs can modulate the cells’ in-vitro immunosuppressive
capacity against T-helper cell subsets.
Brief in-vitro pretreatment of MSCs with poly(I:C) or LPS
induces distinct and opposing immunomodulatory effects
on EAE
To elucidate the therapeutic effect of untreated MSCs
or MSCs pretreated with poly(I:C) or LPS, we induced
EAE in C57BL/6 mice using MOG35–55 immunization
as described previously [12]. MSCs were injected i.p.
(2 × 106 cells/mice) 4 days after EAE induction, and the
clinical scores and body weight loss were recorded daily
until day 27 (Fig. 4a). Control EAE mice showed the
first clinical signs at day 10 post immunization (onset),
reached a peak at day 21, and then presented a stable
disease course until day 27, as we observed previously
[12]. Consistent with previous reports [12], the adminis-
tration of untreated MSCs before the onset of clinical
signs significantly decreased the clinical signs of EAE
compared with control treatment (p < 0.05, Fig. 4a). The
administration of MSCs pretreated with poly(I:C) for
1 hour generated a nonsignificant increase of the thera-
peutic effect on EAE clinical scores relative to untreated
MSCs, decreasing the progress of the disease even fur-
ther (Fig. 4a). In contrast, MSCs pretreated with LPS
completely reversed the protective effect of MSCs
against EAE, showing a similar trend in the clinical
manifestations of the disease to that observed in the
control EAE mice (Fig. 4a). These results were con-
firmed by analyzing the cumulative EAE score, which
showed that untreated MSCs significantly decreased the
clinical signs of EAE compared with the control treat-
ment (p < 0.001, Fig. 4b). On the other hand, MSCs pre-
treated with poly(:C) were even more potent than
untreated MSCs in significantly inhibiting the cumula-
tive EAE score compared with the score of the control
EAE mice (Fig. 4b). In contrast, MSCs pretreated with
LPS significantly reversed the trend observed in the cu-
mulative score induced by untreated MSCs or MSCs
pretreated with poly(I:C) (p < 0.05) (Fig. 4b).
Similarly, analysis of body weight loss demonstrated
that untreated MSCs and MSCs retreated with poly(I:C)
resulted in significantly less weight loss compared with
the control (p < 0.05, Fig. 4c). Finally, the administration
of MSCs pretreated with LPS reversed the effect on body
weight loss induced by untreated MSCs and MSCs
pretreated with poly(I:C) (p < 0.05, Fig. 4c). These data
consistently demonstrate that MSCs pretreated with
poly(I:C) reduce the clinical signs of EAE and that pretreat-
ment of MSCs with LPS reverses this effect, suggesting that
specific TLR activation can alter the immunomodulatory
capacity of MSCs in vivo.
We next evaluated whether the administration of
untreated MSCs could affect Th1 and Th17 cell sub-
sets in EAE mice. Percentages of Th1 and Th17 sub-
sets were analyzed in lymph nodes samples of EAE
mice by flow cytometry as described in Methods. As
expected, treatment with MSCs decreased Th1 and
Th17 subsets in the lymph nodes of EAE mice. We
found a significant effect on the Th17 subset (p <
0.05) and a decrease in the Th1 subset. Interestingly,
pretreatment of MSCs with poly(I:C) was able to signifi-
cantly decrease both the Th1 and Th17 subsets (p < 0.05).
In contrast, the administration of MSCs pretreated with
LPS completely reversed the effect of MSCs on the Th1
and Th17 subsets (p < 0.05, Fig. 5a, b). We observed
higher percentages of Th1 and Th17 in this group, similar
to percentages found in the EAE mice without any
treatment.
Discussion
Recently years, stem cell treatments have become an im-
portant therapeutic strategy for the treatment of various
proinflammatory and autoimmune diseases because of
their powerful immunomodulatory properties via the
suppression of T cells, B cells, natural killer (NK) cells,
and antigen presenting cells [26, 27]. Such immuno-
logical effects have been shown primarily in vitro but
also in vivo, in a number of experimental disease models
such as EAE [10–12], CIA [8], and experimental colitis
[9, 28]. Despite the in-vitro and in-vivo evidence for a
therapeutic effect of MSCs, their precise mechanism of
action and the profile of their adverse effects as immu-
nomodulatory agents are still poorly understood.
Recently, it has been demonstrated that stimulation of
human MSCs with poly(I:C) and LPS induces activation
of NF-kB, mitogen-activated protein kinases (MAPK),
and protein kinase B (AKT) signaling pathways. Activa-
tion of these pathways was associated with the induction
and secretion of different patterns of cytokines and
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chemokines, suggesting that LPS could promote the ac-
tivation of immune responses while poly(I:C) could sup-
press it [29]. Similarly, Waterman et al. [20]
demonstrated that human MSCs polarize into a proin-
flammatory or anti-inflammatory phenotypes, according
to the specific TLR3 or TLR4 activation in vitro. This
functional phenotype was also shown in vivo, in experi-
mental models of diabetes [30] and ovarian cancer [31].
These findings suggest that pretreatment of MSCs with
TLRs could be a powerful and innovative therapeutic tool
for the treatment of autoimmune and proinflammatory
pathologies. In the present study, we evaluated the immu-
nomodulatory effect of murine MSCs after treatment with
TLR3 and TLR4 agonists in vitro and in a mouse model
of multiple sclerosis. Our results demonstrated that pre-
treatment of MSCs with poly(I:C) enhances their im-
munosuppressive capacity in vitro and that intraperitoneal
injection of these MSCs significantly reduces the severity
of EAE. In contrast, LPS pretreatment of MSCs induces
a significant decrease in their immunomodulatory func-
tion in vitro and completely reverses the therapeutic
immunosuppressive effect of MSCs in vivo.
Diverse studies have shown that murine MSCs express
different functional TLRs, such as TLR1–TLR8 [32]. Our
data showed that murine MSCs cultured to 80–90 % con-
fluence in complete culture medium express significant
levels of mRNA for TLR3 and TLR4, and that the expres-
sion level of TLR4 was higher than that of TLR3, similar
to the pattern described by Pevsner-Fischer et al. [32]. In
addition, we demonstrated that pretreatment of these
TLRs for 1 hour with their respective agonists differen-
tially affects the in-vitro immunosuppressive capacity of
murine MSCs. First, we observed that untreated MSCs
were functionally capable of inhibiting the proliferation of
activated T cells, confirming what has been published pre-
viously [7]. Once the inhibitory capacity of the MSCs on
T-cell proliferation was confirmed, we evaluated the effect
of MSCs pretreated for 1 hour with poly(I:C) or LPS.
MSCs pretreated with poly(I:C) were able to significantly
increase the inhibitory capacity of MSCs on T-cell prolif-
eration by approximately 33 % with respect to untreated
MSCs. Conversely, MSCs pretreated with LPS completely
reversed the immunosuppressive effect of untreated MSCs
and induced a significant, and dose-dependent, increase in
T-cell proliferation.
These results demonstrate that brief, in-vitro LPS
stimulation of murine MSCs induces a proinflammatory
phenotype, similar to the effects previously shown by
Waterman et al. [20], using human MSCs.
To better understand the effect of activation of TLR
ligands on the immunomodulatory activity of MSCs, we
measured NO production in the absence or presence of
splenocytes stimulated with ConA as well as the expres-
sion and levels of proinflammatory cytokine IL-6. In the
absence of splenocytes, no differences were observed in
NO secreted by untreated or pretreated MSCs. However,
a b
Fig. 5 Pretreatment of MSCs with poly(I:C) and LPS generated a differential modulation of Th1 and Th17 cells in EAE mice. Lymph nodes were
removed from different groups of treatments at day 27. (a) Th1 detection using CD4+IFN-γ for the five groups of mice. (b) Th17 detection (CD4
+IL-17+) for the five groups of mice. Bars represent the mean ± SEM, significant differences calculated using t tests (*p < 0.05, **p < 0.001).
MSCsPoly MSCs pretreated with poly(I:C) for 1 hour, MSCsLPS MSCs pretreated with LPS for 1 hour
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in the presence of splenocytes, we detected a significant
increase in NO production induced by MSCs pretreated
with poly(I:C) but not by those pretreated with LPS, which
had lower NO production compared with untreated
MSCs. On the other hand, our results indicated that the
expression of IL-6 increased after stimulation of MSCs
with LPS and was inhibited after stimulation of MSCs
with poly(I:C). Taken together, these data provide evidence
of a based anti-inflammatory phenotype for MSCs pre-
treated with poly(I:C) and an opposite, proinflammatory
phenotype for MSCs stimulated with LPS, which show a
loss of capacity to inhibit T-cell proliferation, a higher
expression of IL-6, and nonsignificant NO secretion.
MSCs have been identified as immunomodulating cells
because they inhibit the generation and function of Th1
and Th17 cells and increase Treg cell formation [33–36].
Previous studies from our laboratory showed that MSCs
cocultured with CD4+ T cells grown in conditions polariz-
ing them towards Th1 or Th17 lineages exert strong Th1
immunosuppression but have little effect on Th17 cells
[22, 25]. Here, we evaluated the immunomodulatory effect
of TLR3 and TLR4-pretreated MSCs on Th1 and Th17
differentiation and proliferation in vitro. We observed a
strong capacity of MSCs pretreated with poly(I:C) to in-
hibit Th1 and Th17 differentiation and proliferation,
which was even more pronounced than the effect of
untreated MSCs. Conversely, MSCs pretreated with LPS
showed a diminished capacity to inhibit Th1 and Th17
differentiation and proliferation.
Recently, we studied the therapeutic effect of MSC
administration on EAE, showing that the injection of
MSCs at the time of disease onset induces a significant
improvement in the clinical signs of the disease [12]. In
the present study, using the same mouse model, we
studied whether the administration of MSCs pretreated
with poly(I:C) or LPS generated distinct therapeutic ef-
fects in vivo. Our results demonstrated that MSCs
pretreated with poly(I:C) significantly reduce the clinical
signs of EAE and that pretreatment of MSCs with LPS
completely reverses the therapeutic immunosuppressive
effect of MSCs. Furthermore, when we evaluated the cu-
mulative score and the weight loss of the animals in each
group, we found the same pattern that again highlighted
the ability of MSCs stimulated with poly(I:C) to increase
the immunosuppressive capacity of the MSCs. Poly(I:C)
stimulation generated a decrease in the score and weight
loss in the treated animals, while LPS caused an increase
in clinical signs and a high percentage of weight loss in
animals. In addition, we investigated the relationship be-
tween the treatments of the animals with respect to Th1
and Th17 proinflammatory cell subsets in the lymph
node of EAE mice as a way to account for the observed
results. We found a significant decrease of the Th1 and
Th17 subsets induced by the administration of untreated
MSCs, although these differences were significant only
in the case of Th17 cells. No significant differences were
observed in the expression of Th1 and Th17 cells when
EAE mice were injected with poly(I:C)-pretreated MSCs
in comparison with the expression in untreated MSCs.
In contrast, the treatment of EAE mice with LPS-
pretreated MSCs completely reversed the effect on the
Th1 and Th17 subset cells induced by untreated MSCs.
Conclusions
In summary, for the first time we found that murine
MSCs polarize into two distinct phenotypes following in-
vitro specific TLR activation, as observed in humans.
TLR3 stimulation specifically leads to enhancement of the
immunosuppressive capacity to inhibit the proliferation of
splenocytes and the differentiation and proliferation of
Th1 and Th17 in vitro. Meanwhile, TLR4 stimulation
completely reverses these immunomodulatory effects. Sec-
ondly, we also examined these phenotypes in the context
of the autoimmune disease model of multiple sclerosis,
where pretreatment of murine MSCs with TLR3 and
TLR4 agonists generates distinct and opposing immuno-
modulatory effects on EAE. Our findings are important to
better define strategies of cell-based therapies for proin-
flammatory and autoimmune diseases.
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